Xiang Sheng Li1, Hong Xia Fan1, Hong Fang1, Yun Long Song1, Chun Wu Zhou2. 1. Department of MRI, Air Force General Hospital, People's Liberation Army, Beijing, China. 2. Department of Radiology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Abstract
BACKGROUND: To prospectively investigate the value of R2* in predicting the prognosis of advanced cervical squamous carcinoma treated with concurrent chemoradiotherapy. METHODS: Sixty-five patients with biopsy-proven cervical squamous carcinoma were enrolled in our study. All these subjects underwent multi-echo T2*-weighted MR imaging on a 3.0 Tesla MR scanner, and tumor R2* was calculated. The patients were divided into the responders and the nonresponders according to treatment effect. Tumor R2* values of these two groups were compared. The relationship between tumor R2* and prognosis after therapy was analyzed. RESULTS: The responder group had lower R2* value than the nonresponder group (P = 0.02). The area under the receiver operating characteristics curve for tumor R2* in discriminating responders from nonresponders was 0.769. A cutoff value of 23.87 Hz for tumor R2* resulted in a sensitivity of 78.3% and a specificity of 67.6%. The low R2* group (≤28.37 Hz) had longer median progression-free survival period and overall survival period (P = 0.01, 0.03). Multivariate analysis showed that tumor R2* was a significant prognostic factor for progression-free survival and overall survival (adjusted hazards ratio = 5.34, 4.78; P = 0.02, 0.01). CONCLUSION: R2* value obtained from T2*-weighted imaging, as an imaging biomarker, may be an important predictor for the prognosis of advanced cervical squamous carcinoma treated with concurrent chemoradiotherapy.
BACKGROUND: To prospectively investigate the value of R2* in predicting the prognosis of advanced cervical squamous carcinoma treated with concurrent chemoradiotherapy. METHODS: Sixty-five patients with biopsy-proven cervical squamous carcinoma were enrolled in our study. All these subjects underwent multi-echo T2*-weighted MR imaging on a 3.0 Tesla MR scanner, and tumor R2* was calculated. The patients were divided into the responders and the nonresponders according to treatment effect. Tumor R2* values of these two groups were compared. The relationship between tumor R2* and prognosis after therapy was analyzed. RESULTS: The responder group had lower R2* value than the nonresponder group (P = 0.02). The area under the receiver operating characteristics curve for tumor R2* in discriminating responders from nonresponders was 0.769. A cutoff value of 23.87 Hz for tumor R2* resulted in a sensitivity of 78.3% and a specificity of 67.6%. The low R2* group (≤28.37 Hz) had longer median progression-free survival period and overall survival period (P = 0.01, 0.03). Multivariate analysis showed that tumor R2* was a significant prognostic factor for progression-free survival and overall survival (adjusted hazards ratio = 5.34, 4.78; P = 0.02, 0.01). CONCLUSION: R2* value obtained from T2*-weighted imaging, as an imaging biomarker, may be an important predictor for the prognosis of advanced cervical squamous carcinoma treated with concurrent chemoradiotherapy.
Authors: Kee H Wong; Rafal Panek; Shreerang A Bhide; Christopher M Nutting; Kevin J Harrington; Katie L Newbold Journal: Br J Radiol Date: 2017-03 Impact factor: 3.039
Authors: Pelin A Ciris; Mukund Balasubramanian; Antonio L Damato; Ravi T Seethamraju; Clare M Tempany-Afdhal; Robert V Mulkern; Akila N Viswanathan Journal: J Magn Reson Imaging Date: 2016-03-12 Impact factor: 4.813
Authors: Derek A White; Zhang Zhang; Li Li; Jeni Gerberich; Strahinja Stojadinovic; Peter Peschke; Ralph P Mason Journal: Cancer Lett Date: 2016-06-03 Impact factor: 8.679
Authors: Myo Min; Mark T Lee; Peter Lin; Lois Holloway; Dj Wijesekera; Dinesh Gooneratne; Robba Rai; Wei Xuan; Allan Fowler; Dion Forstner; Gary Liney Journal: Br J Radiol Date: 2015-12-09 Impact factor: 3.039
Authors: Christopher N Rumley; Mark T Lee; Lois Holloway; Robba Rai; Myo Min; Dion Forstner; Allan Fowler; Gary Liney Journal: BMC Cancer Date: 2017-07-10 Impact factor: 4.430
Authors: Kee H Wong; Rafal Panek; Alex Dunlop; Dualta Mcquaid; Angela Riddell; Liam C Welsh; Iain Murray; Dow-Mu Koh; Martin O Leach; Shreerang A Bhide; Christopher M Nutting; Wim J Oyen; Kevin J Harrington; Kate L Newbold Journal: Eur J Nucl Med Mol Imaging Date: 2017-11-21 Impact factor: 9.236
Authors: Nicole Wiedenmann; Hatice Bunea; Hans C Rischke; Andrei Bunea; Liette Majerus; Lars Bielak; Alexey Protopopov; Ute Ludwig; Martin Büchert; Christian Stoykow; Nils H Nicolay; Wolfgang A Weber; Michael Mix; Philipp T Meyer; Jürgen Hennig; Michael Bock; Anca L Grosu Journal: Radiat Oncol Date: 2018-08-29 Impact factor: 3.481